At the 2025 American Society of Hematology (ASH) Annual Meeting, Stefan Ciurea, MD, UCI Health hematologist-oncologist, shared updated findings from a large real-world analysis of more than 11,000 patients examining conditioning regimens for older adults with AML and MDS undergoing transplant.

Building on prior work published in Blood, this follow-up analysis by UCI Health hematologic-oncologist Piyanuch Kongtim, MD, reinforces the role of reduced-intensity conditioning in older patients, with particular support for fludarabine and melphalan–based approaches.

Ciurea emphasizes that age, physiologic reserve and toxicity risk must remain central to conditioning decisions, and points toward future studies focused on better individualized conditioning intensity for this growing patient population.

As cellular transplant strategies continue to evolve, large-scale data sets like this are helping refine best practices for cancer care.